DOCSLIB.ORG

A NOVEL Cerna ANALYSIS for LMNA and ZMPSTE24 RELATED to MECHANISMS of PROGEROID LAMINOPATHIES

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

EJONS International Journal on Mathematic, Engineering and Natural Sciences ISSN 2602 - 4136 Article Arrival Date Article Type Article Published Date 18.05.2020 Research Article 12.06.2020 Doi Number: http://dx.doi.org/10.38063/ejons.251 A NOVEL ceRNA ANALYSIS FOR LMNA AND ZMPSTE24 RELATED TO MECHANISMS OF PROGEROID LAMINOPATHIES Nazlı Irmak GİRİTLİOĞLU Molecular Biologist and Bioengineering Specialist, Istanbul/Turkey [email protected], https://orcid.org/0000-0001-5034-0984 ABSTRACT Progeroid syndromes are diseases that display old-age features such as skin aging (loss of elastin and skin thinning), cardiovascular problems, alopecia at young ages. One of the most known progeroid syndromes is Hutchinson-Gilford Progeria Syndrome (HGPS). HGPS is caused by LMNA de novo point mutation and as a result, a toxic protein that accumulates in the inner nuclear membrane called progerin is produced. Zinc Metallopeptidase STE24 (ZMPSTE24, also known as FACE-1 in humans) is an enzyme that has important functions in post-translational modifications. ZMPSTE24 mutations also can cause progeroid syndromes. Competing endogenous RNA (ceRNA) is a relatively new hypothesis that claims RNAs communicate with each other and regulate each other’s expressions via shared microRNA (miRNA)s. In this study, a ceRNA analysis was performed for mRNAs of LMNA and ZMPSTE24. Firstly, related miRNAs of LMNA and ZMPSTE24 mRNAs were found in miRTarBase, and the results with both strong and less strong evidence were considered. Then, other genes related to these miRNAs that have only strong evidence in miRTarBase were chosen and hit scores of these genes were calculated. The Gene Ontology (GO) Resource GO Enrichment analysis 359 algorithm was used for P values (<0.05) of molecular functions of these genes which have the highest hit scores. The highest hit score of transcripts associated with LMNA mRNAs is 3 (BCL2, CCND1, CCND2, CDK6, EZH2) and the highest hit score of transcripts associated with ZMPSTE24 mRNAs is 2 (CBL, CCND2, CLOCK, EZH2, MAPK14, SERP1). The most important result in this study is EZH2 interaction with both LMNA and ZMPSTE24 networks and its epigenetic involvement might be key for treatments of some progeroid syndromes. It was known that downregulated EZH2 with loss of the H3K27me3 marks causes the weaker heterochromatin-lamina associations. The study provides a novel analysis for connected ceRNAs of LMNA and ZMPSTE24 mRNAs. Keywords: ceRNA, miRNA, Progeroid, LMNA, ZMPSTE24 1. INTRODUCTION Nuclear lamins (type V intermediate filament proteins) are important, structural components of the proteinaceous meshwork called nuclear lamina (NL), and directly associated with the nuclear genome. NL provides a proper morphology to cells and has regulatory functions on epigenetic mechanisms (Hah & Kim, 2019). Lamins are capable of binding to chromatin, DNA, and histones (Shevelyov & Ulianov, 2019) so they control gene expressions. Vertebrates have two A type of lamins (lamins A and C) that are encoded by LMNA, also there are less abundant isoforms (lamin A10 ve C2) (Dechat, Adam, Taimen, Shimi, & Goldman, 2010). A-type lamins are expressed in most somatic cell lines but not in undifferentiated pluripotent stem cells (Chojnowski, Ong, & Dreesen, 2015). Accelerated aging syndromes comprise of the many types of diseases which include classical/non- classical HGPS (both of them progerin producing type), non-progerin producing progeroid laminopathies (in consequence of heterozygous LMNA pathogenic variant or pathogenic variants in other genes such as ZMPSTE24), non-progeroid laminopathies, and non-laminopathy progeroid Year 4 (2020) Vol:14 Issued in JUNE, 2020 www.ejons.co.uk EJONS International Journal on Mathematic, Engineering and Natural Sciences ISSN 2602 - 4136 syndromes (Gordon, Brown, & Collins, 2003). Laminopathies are caused by the genes (LMNA, LMNB1, and LMNB2) which express the lamin proteins and LMNA mutations are the most involved type of these diseases such as muscular dystrophy, neuropathy, cardiomyopathy, metabolic disorders, and accelerated aging and their combinations (Ho & Hegele, 2019). HGPS is one of the most known type of progeroid syndromes and caused by an aberrant process in post-translational modification of prelamin A. Cytosine (C) changes to thymine (T) in LMNA exon 11 (c.1824C>T, G608G). Prelamin A has CAAX (C=cysteine, A=aliphatic amino acid, and x=any amino acid) motif that goes through some processes at the C-terminus: 1) Farnesyltransferase adds a farnesyl group to Cysteine, 2) aaX aminoacids are cleavaged by zinc metalloproteinase (ZMPSTE24 or also known as FACE-1), 3) Prenylcysteine carboxy methyltransferase adds a carboxymethyl group to farnesylated cysteine, and 4) 15 terminal amino acid residues are cleavaged by ZMPSTE24. In HGPS, ZMPSTE24 does not recognize the second cleavage site because of the de novo LMNA mutation (then aberrant mRNA splicing) and a toxic protein is formed called progerin (Eriksson et al., 2003; Ramirez, Cadinanos, Varela, Freije, & Lopez-Otin, 2007). When the functional lamin A concentration is low, the cell would be more unstable, and external forces can easily affect it (Al- Saaidi & Bross, 2015). If the farnesylated prelamin A accumulates in the inner nuclear membrane, nuclear blebbing occurs (Yang et al., 2005). Mutations in ZMPSTE24 also cause progeroid syndromes. Denecke et al. report a patient with homozygous ZMPSTE24 null mutation and heterozygous LMNA mutation (Denecke et al., 2006). Shackleton et al. describe a 2 years old female patient that shows characteristics of HGPS, mandibuloacral dysplasia, and restrictive dermopathy with compound heterozygous ZMPSTE24 mutations (Shackleton et al., 2005). miRNAs are short (approximately 19-25 nucleotide), endogenous RNA molecules and basically, they have functions in gene silencing (Lu & Rothenberg, 2018). RNA-RNA interactions can comprise the regulations of RNA transcripts by miRNAs. In this context, ceRNA is a potent hypothesis that specifies the mRNAs of genes communicate between them and control each other’s expressions with 360 miRNAs (Tay, Rinn, & Pandolfi, 2014). There are some computational algorithms such as mirWalk (Dweep, Sticht, Pandey, & Gretz, 2011) or mirTaRBase (Huang et al., 2019) to show miRNAs that associate with mRNAs. Counts of shared miRNAs for mRNAs are indicated the connections between these mRNAs. In this study, ceRNAs of LMNA and ZMPSTE24 mRNAs were searched in bioinformatic tools and the potential ceRNAs were discussed. 2. MATERIALS AND METHODS 2.1. Detection of related miRNAs of LMNA and ZMPSTE24 mRNAs based on strong and less strong evidence Related miRNAs of LMNA and ZMPSTE24 mRNAs were detected in miRTarBase which is a database that shows the validated miRNAs with strong and less strong experimental evidence (Huang et al., 2019) (Table 1 and Table 2). Year 4 (2020) Vol:14 Issued in JUNE, 2020 www.ejons.co.uk EJONS International Journal on Mathematic, Engineering and Natural Sciences ISSN 2602 - 4136 Table 1. LMNA mRNAs related miRNAs with strong and less strong valuation methods in miRTarBase (http://mirtarbase.cuhk.edu.cn/php/index.php) Target miRTarbase ID miRNA Sequence Valuation Methods Site MIRT019532 hsa-miR-340-5p UUAUAAAGCAAUGAGACUGAUU 3' UTR NGS MIRT021388 hsa-miR-9-5p UCUUUGGUUAUCUAGCUGUAUGA 3' UTR Microarray MIRT022394 hsa-miR-124-3p UAAGGCACGCGGUGAAUGCC 3' UTR Microarray and other MIRT038445 hsa-miR-296-3p GAGGGUUGGGUGGAGGCUCUCC 3' UTR NGS MIRT040169 hsa-miR-615-3p UCCGAGCCUGGGUCUCCCUCUU 3' UTR NGS MIRT051592 hsa-let-7e-5p UGAGGUAGGAGGUUGUAUAGUU 3' UTR NGS MIRT052409 hsa-let-7a-5p UGAGGUAGUAGGUUGUAUAGUU 3' UTR NGS Reporter assay and MIRT731197 hsa-miR-205-5p UCCUUCAUUCCACCGGAGUCUG 3' UTR microarray Table 2. ZMPSTE24 mRNAs related miRNAs with strong and less strong valuation methods in miRTarBase (http://mirtarbase.cuhk.edu.cn/php/index.php) Target miRTarbase ID miRNA Sequence Valuation Methods Site MIRT004942 hsa-miR-98-5p UGAGGUAGUAAGUUGUAUUGUU 3' UTR qPCR and other MIRT022576 hsa-miR-124-3p UAAGGCACGCGGUGAAUGCC 3' UTR Microarray MIRT438256 hsa-miR-141-3p UAACACUGUCUGGUAAAGAUGG 3' UTR Reporter assay 2.2. Determining the genes associated with LMNA and ZMPSTE24 miRNAs and calculating the hit scores of the potential ceRNAs All the miRNAs in Table 1 and Table 2 were searched in miRTarBase and the genes with only the strong evidence grade were selected (Table 3 and Table 4). 361 Hit score in this study means that the number of the genes according to their shared miRNAs. For example; BCL in Table 3 shares three miRNAs on the strong evidence grade with LMNA, so the hit score of BCL is 3. 2.3. GO molecular function analysis of the potential LMNA and ZMPSTE24 ceRNAs “Molecular function” term explains the functional activities of the gene products at the molecular level. The genes which have the highest hit scores were inserted into GO Enrichment Analysis (powered by PANTHER) algorithm (http://geneontology.org/) and “Molecular function” and “Homo sapiens” were selected. P values (<0.05) were ordered from the lowest to the highest (Table 7 and Table 8). Year 4 (2020) Vol:14 Issued in JUNE, 2020 www.ejons.co.uk EJONS International Journal on Mathematic, Engineering and Natural Sciences ISSN 2602 - 4136 Table 3. The genes that their expressions are regulated by the same miRNAs with LMNA miRNA Genes with strong evidence CCND1, CCND2, CDK6, HNRNPA2B1, KRAS, MECP2, MET, PTBP1, PUM1, hsa-miR-340-5p PUM2, RHOA, ROCK1, SKP2, SOX2 ACAT1, AP3B1, ATG5, BACE1, BCL2, BCL2L11, BCL6, CCND1, CCNG1, CD34, CDH1, CDX2, CHMP2B,
Recommended publications
  • Mutations in CHMP2B in Lower Motor Neuron Predominant Amyotrophic Lateral Sclerosis (ALS)

    Mutations in CHMP2B in Lower Motor Neuron Predominant Amyotrophic Lateral Sclerosis (ALS)

    This is a repository copy of Mutations in CHMP2B in lower motor neuron predominant amyotrophic lateral sclerosis (ALS). White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/10846/ Article: Cox, L.E., Ferraiuolo, L., Goodall, E.F. et al. (13 more authors) (2010) Mutations in CHMP2B in lower motor neuron predominant amyotrophic lateral sclerosis (ALS). Plos One, 5 (3). Art no.e9872. ISSN 1932-6203 https://doi.org/10.1371/journal.pone.0009872 Reuse Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher’s website. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Mutations in CHMP2B in Lower Motor Neuron Predominant Amyotrophic Lateral Sclerosis (ALS) Laura E. Cox1, Laura Ferraiuolo1, Emily F. Goodall1, Paul R. Heath1, Adrian Higginbottom1, Heather Mortiboys1, Hannah C. Hollinger1, Judith A. Hartley1, Alice Brockington1, Christine E.
  • ELOVL5 Rabbit Polyclonal Antibody – TA338477 | Origene

    ELOVL5 Rabbit Polyclonal Antibody – TA338477 | Origene

    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for TA338477 ELOVL5 Rabbit Polyclonal Antibody Product data: Product Type: Primary Antibodies Applications: WB Recommended Dilution: WB Reactivity: Human Host: Rabbit Isotype: IgG Clonality: Polyclonal Immunogen: The immunogen for anti-ELOVL5 antibody: synthetic peptide directed towards the N terminal of human ELOVL5. Synthetic peptide located within the following region: EHFDASLSTYFKALLGPRDTRVKGWFLLDNYIPTFICSVIYLLIVWLGPK Formulation: Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose. Note that this product is shipped as lyophilized powder to China customers. Purification: Affinity Purified Conjugation: Unconjugated Storage: Store at -20°C as received. Stability: Stable for 12 months from date of receipt. Predicted Protein Size: 35 kDa Gene Name: ELOVL fatty acid elongase 5 Database Link: NP_068586 Entrez Gene 60481 Human Q9NYP7 Background: ELOVL5 plays a role in elongation of long-chain polyunsaturated fatty acids.ELOVL5 plays a role in elongation of long-chain polyunsaturated fatty acids (Leonard et al., 2000 [PubMed 10970790]). [supplied by OMIM]. PRIMARYREFSEQ_SPAN PRIMARY_IDENTIFIER PRIMARY_SPAN COMP 1-3003 AF338241.1 9-3011 Synonyms: dJ483K16.1; HELO1; SCA38 This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies,
  • Genetic Screen Identifies Serpin5 As a Regulator of the Toll Pathway and CHMP2B Toxicity Associated with Frontotemporal Dementia

    Genetic Screen Identifies Serpin5 As a Regulator of the Toll Pathway and CHMP2B Toxicity Associated with Frontotemporal Dementia

    Genetic screen identifies serpin5 as a regulator of the toll pathway and CHMP2B toxicity associated with frontotemporal dementia S. Tariq Ahmada, Sean T. Sweeneyb, Jin-A Leea, Neal T. Sweeneya,c,1, and Fen-Biao Gaoa,c,2 aGladstone Institute of Neurological Disease, San Francisco, CA 94158; bDepartment of Biology, University of York, P.O. Box 373, York YO10 5YW, United Kingdom; and cNeuroscience Graduate Program, University of California, San Francisco, CA 94158 Edited by Yuh Nung Jan, University of California School of Medicine, San Francisco, CA, and approved May 18, 2009 (received for review March 23, 2009) Frontotemporal dementia (FTD) is the most common form of demen- gain-of-function mechanism. However, animal models of FTD3 tia before 60 years of age. Rare pathogenic mutations in CHMP2B, have not been reported, and the signaling pathways that are which encodes a component of the endosomal sorting complex misregulated in vivo remain to be identified. required for transport (ESCRT-III), are associated with FTD linked to In recent years, Drosophila models have been instrumental in chromosome 3 (FTD3). Animal models of FTD3 have not yet been uncovering molecular pathways that contribute to the pathogenesis reported, and what signaling pathways are misregulated by mutant of neurodegenerative diseases (17, 18). In this study, we modeled CHMP2B in vivo is unknown. Here we report the establishment of a the effect of CHMP2B in human FTD3 using a gain-of-function Drosophila model of FTD3 and show the genetic interactions between approach, which is similar to the approach that gives effects in mutant CHMP2B and other components of ESCRT.
  • Small Cell Ovarian Carcinoma: Genomic Stability and Responsiveness to Therapeutics

    Small Cell Ovarian Carcinoma: Genomic Stability and Responsiveness to Therapeutics

    Gamwell et al. Orphanet Journal of Rare Diseases 2013, 8:33 http://www.ojrd.com/content/8/1/33 RESEARCH Open Access Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics Lisa F Gamwell1,2, Karen Gambaro3, Maria Merziotis2, Colleen Crane2, Suzanna L Arcand4, Valerie Bourada1,2, Christopher Davis2, Jeremy A Squire6, David G Huntsman7,8, Patricia N Tonin3,4,5 and Barbara C Vanderhyden1,2* Abstract Background: The biology of small cell ovarian carcinoma of the hypercalcemic type (SCCOHT), which is a rare and aggressive form of ovarian cancer, is poorly understood. Tumourigenicity, in vitro growth characteristics, genetic and genomic anomalies, and sensitivity to standard and novel chemotherapeutic treatments were investigated in the unique SCCOHT cell line, BIN-67, to provide further insight in the biology of this rare type of ovarian cancer. Method: The tumourigenic potential of BIN-67 cells was determined and the tumours formed in a xenograft model was compared to human SCCOHT. DNA sequencing, spectral karyotyping and high density SNP array analysis was performed. The sensitivity of the BIN-67 cells to standard chemotherapeutic agents and to vesicular stomatitis virus (VSV) and the JX-594 vaccinia virus was tested. Results: BIN-67 cells were capable of forming spheroids in hanging drop cultures. When xenografted into immunodeficient mice, BIN-67 cells developed into tumours that reflected the hypercalcemia and histology of human SCCOHT, notably intense expression of WT-1 and vimentin, and lack of expression of inhibin. Somatic mutations in TP53 and the most common activating mutations in KRAS and BRAF were not found in BIN-67 cells by DNA sequencing.
  • IGF2BP1 (D-9): Sc-166344

    IGF2BP1 (D-9): Sc-166344

    SANTA CRUZ BIOTECHNOLOGY, INC. IGF2BP1 (D-9): sc-166344 BACKGROUND STORAGE Insulin like growth factor 2 mRNA binding proteins (IGF2BPs) bind RNA and Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of influence RNA synthesis and metabolism. IGF2BP1, also known as coding shipment. Non-hazardous. No MSDS required. region determinant-binding protein/Insulin-like growth factor II mRNA-binding protein (CRD-BP), IMP1 or VICKZ1; IGF2BP2 (IMP2, VICKZ2, p62); and IGF2BP2 DATA (IMP3, KOC1, VICKZ3) contain a unique combination of RNA recognition motifs A B and four hnRNP K homology domains. IGF2BP1 is abundant in embryonal ABC DEF tissues and is expressed in 81% of colon cancers, 73% of sarcomas and 132 K – 58.5% of breast cancers. It recognizes c-Myc, IGF-II and t mRNAs, and H19 90 K – RNA, and plays a major role in proliferation of K-562 cells by an IGF-II-depen- 55 K – IGF2BP1 dent mechanism. IGF2BP2 binds the 5' UTR of IGF-II mRNA and influences tumor cell growth, in which IGF2BP2 is associated with apoptosis induced 43 K – by tretinoin. IGF2BP3 knockdown by RNA interference decreases levels of IGF-II protein without affecting IGF-II, c-Myc, or b Actin mRNA and H19 RNA levels. IGF2BP3 is a marker for carcinomas and high-grade dysplastic lesions IGF2BP1 (D-9): sc-166344. Western blot analysis IGF2BP1 (D-9): sc-166344. Immunofluorescence staining ofIGF2BP1 expressioninHEK293 (A), NIH/3T3 (B), of methanol-fixed HeLa cells showing nucleolar and of pancreatic ductal epithelium. K-562 (C), U-698-M (D) and Raji (E)wholecell lysates cytoplasmic localization (A).
  • ACAT) in Cholesterol Metabolism: from Its Discovery to Clinical Trials and the Genomics Era

    ACAT) in Cholesterol Metabolism: from Its Discovery to Clinical Trials and the Genomics Era

    H OH metabolites OH Review Acyl-Coenzyme A: Cholesterol Acyltransferase (ACAT) in Cholesterol Metabolism: From Its Discovery to Clinical Trials and the Genomics Era Qimin Hai and Jonathan D. Smith * Department of Cardiovascular & Metabolic Sciences, Cleveland Clinic, Cleveland, OH 44195, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-216-444-2248 Abstract: The purification and cloning of the acyl-coenzyme A: cholesterol acyltransferase (ACAT) enzymes and the sterol O-acyltransferase (SOAT) genes has opened new areas of interest in cholesterol metabolism given their profound effects on foam cell biology and intestinal lipid absorption. The generation of mouse models deficient in Soat1 or Soat2 confirmed the importance of their gene products on cholesterol esterification and lipoprotein physiology. Although these studies supported clinical trials which used non-selective ACAT inhibitors, these trials did not report benefits, and one showed an increased risk. Early genetic studies have implicated common variants in both genes with human traits, including lipoprotein levels, coronary artery disease, and Alzheimer’s disease; however, modern genome-wide association studies have not replicated these associations. In contrast, the common SOAT1 variants are most reproducibly associated with testosterone levels. Keywords: cholesterol esterification; atherosclerosis; ACAT; SOAT; inhibitors; clinical trial Citation: Hai, Q.; Smith, J.D. Acyl-Coenzyme A: Cholesterol Acyltransferase (ACAT) in Cholesterol Metabolism: From Its 1. Introduction Discovery to Clinical Trials and the The acyl-coenzyme A:cholesterol acyltransferase (ACAT; EC 2.3.1.26) enzyme family Genomics Era. Metabolites 2021, 11, consists of membrane-spanning proteins, which are primarily located in the endoplasmic 543. https://doi.org/10.3390/ reticulum [1].
  • Exome Sequencing Revealed DNA Variants in NCOR1, IGF2BP1, SGLT2 and NEK11 As Potential Novel Causes of Ketotic Hypoglycemia in C

    Exome Sequencing Revealed DNA Variants in NCOR1, IGF2BP1, SGLT2 and NEK11 As Potential Novel Causes of Ketotic Hypoglycemia in C

    www.nature.com/scientificreports OPEN Exome sequencing revealed DNA variants in NCOR1, IGF2BP1, SGLT2 and NEK11 as potential novel causes of ketotic hypoglycemia in children Yazeid Alhaidan1,2,3,4*, Martin J. Larsen 1,2, Anders Jørgen Schou5, Maria H. Stenlid6, Mohammed A. Al Balwi 3,4, Henrik Thybo Christesen2,5,7,9 & Klaus Brusgaard1,2,8,9 Unexplained or idiopathic ketotic hypoglycemia (KH) is the most common type of hypoglycemia in children. The diagnosis is based on the exclusion of routine hormonal and metabolic causes of hypoglycemia. We aimed to identify novel genes that cause KH, as this may lead to a more targeted treatment. Deep phenotyping of ten preschool age at onset KH patients (boys, n = 5; girls, n = 5) was performed followed by trio exome sequencing and comprehensive bioinformatics analysis. Data analysis revealed four novel candidate genes: (1) NCOR1 in a patient with KH, iron defciency and loose stools; (2) IGF2BP1 in a proband with KH, short stature and delayed bone age; (3) SLC5A2 in a proband with KH, intermittent glucosuria and extremely elevated p-GLP-1; and (4) NEK11 in a proband with ketotic hypoglycemia and liver afiction. These genes are associated with diferent metabolic processes, such as gluconeogenesis, translational regulation, and glucose transport. In conclusion, WES identifed DNA variants in four diferent genes as potential novel causes of IKH, suggesting that IKH is a heterogeneous disorder that can be split into several novel diseases: NCOR1-KH, IGF2BP1-KH, SGLT2-KH or familial renal glucosuria KH, and NEK11-KH. Precision medicine treatment based on exome sequencing may lead to advances in the management of IKH.
  • A Rac/Cdc42 Exchange Factor Complex Promotes Formation of Lateral filopodia and Blood Vessel Lumen Morphogenesis

    A Rac/Cdc42 Exchange Factor Complex Promotes Formation of Lateral filopodia and Blood Vessel Lumen Morphogenesis

    ARTICLE Received 1 Oct 2014 | Accepted 26 Apr 2015 | Published 1 Jul 2015 DOI: 10.1038/ncomms8286 OPEN A Rac/Cdc42 exchange factor complex promotes formation of lateral filopodia and blood vessel lumen morphogenesis Sabu Abraham1,w,*, Margherita Scarcia2,w,*, Richard D. Bagshaw3,w,*, Kathryn McMahon2,w, Gary Grant2, Tracey Harvey2,w, Maggie Yeo1, Filomena O.G. Esteves2, Helene H. Thygesen2,w, Pamela F. Jones4, Valerie Speirs2, Andrew M. Hanby2, Peter J. Selby2, Mihaela Lorger2, T. Neil Dear4,w, Tony Pawson3,z, Christopher J. Marshall1 & Georgia Mavria2 During angiogenesis, Rho-GTPases influence endothelial cell migration and cell–cell adhesion; however it is not known whether they control formation of vessel lumens, which are essential for blood flow. Here, using an organotypic system that recapitulates distinct stages of VEGF-dependent angiogenesis, we show that lumen formation requires early cytoskeletal remodelling and lateral cell–cell contacts, mediated through the RAC1 guanine nucleotide exchange factor (GEF) DOCK4 (dedicator of cytokinesis 4). DOCK4 signalling is necessary for lateral filopodial protrusions and tubule remodelling prior to lumen formation, whereas proximal, tip filopodia persist in the absence of DOCK4. VEGF-dependent Rac activation via DOCK4 is necessary for CDC42 activation to signal filopodia formation and depends on the activation of RHOG through the RHOG GEF, SGEF. VEGF promotes interaction of DOCK4 with the CDC42 GEF DOCK9. These studies identify a novel Rho-family GTPase activation cascade for the formation of endothelial cell filopodial protrusions necessary for tubule remodelling, thereby influencing subsequent stages of lumen morphogenesis. 1 Institute of Cancer Research, Division of Cancer Biology, 237 Fulham Road, London SW3 6JB, UK.
  • Profilin-1 Is Required for Survival of Adult Hematopoietic Stem Cells

    Profilin-1 Is Required for Survival of Adult Hematopoietic Stem Cells

    Extended methods Immunohistochemistry HepG-2, SMMC-7721, and 293T cells were obtained from Cell Resource Center of Shanghai Institute for Biological Science, Chinese Academy Science, Shanghai, China. HUVEC cells were kindly provided by Prof. Ping-Jin Gao at Institute of Health Sciences (Shanghai, China). All these cell lines were cultured in DMEM with 10% FBS. MDA- MB-231 cell line was kindly provided by Prof. Ming-Yao Liu (East China Normal University, Shanghai, China) and was cultured in Leibovitz L-15 medium with 10% FBS. All these cell lines were originally purchased from ATCC. MDA-MB-231, SMMC-7721 or HepG2 cells were grown on coverslips in 24-well plates and fixed in either 4% paraformaldehyde or pre-chilled methanol (-20°C) for 10 min. In some cases, WT or VPS33B-null Lin-Sca-1+c-Kit+Flk2-CD34- LT-HSCs were collected by flow cytometry and fixed for immunofluorescence staining. Cells were then blocked with 3% BSA in PBS for 60 min followed by incubation with primary antibodies overnight. The antibodies used were anti-HA (Sigma), anti-Flag (Sigma), anti-VPS33B (Sigma), anti- VPS16B (Abcam), anti-GDI2 (Proteintech), anti-LAMP1 (Proteintech), anti-FLOT1 (Abways), anti-CD63 (Proteintech), anti-ANGPTL2 (R&D system), anti-ANGPTL3 (R&D system), anti-TPO (Abways), anti-GLUT1 (Proteintech), anti-LDHA (Proteintech), anti-PKM2 (CST), anti-RAB11A (Abways), anti-RAB27A (Abways) and anti-V5 (Biodragon). Fluorescent-conjugated secondary antibodies (Alexa Fluor® 488 or Alexa Fluor® 555) against mouse, rabbit, or goat were obtained from the Thermo Scientific Inc. The details for all the antibodies are listed in Table S3.
  • Differential Requirements for Tousled-Like Kinases 1 and 2 in Mammalian Development

    Differential Requirements for Tousled-Like Kinases 1 and 2 in Mammalian Development

    Cell Death and Differentiation (2017) 24, 1872–1885 & 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved 1350-9047/17 www.nature.com/cdd Differential requirements for Tousled-like kinases 1 and 2 in mammalian development Sandra Segura-Bayona1,8, Philip A Knobel1,8, Helena González-Burón1,8, Sameh A Youssef2,3, Aida Peña-Blanco1, Étienne Coyaud4,5, Teresa López-Rovira1, Katrin Rein1, Lluís Palenzuela1, Julien Colombelli1, Stephen Forrow1, Brian Raught4,5, Anja Groth6, Alain de Bruin2,7 and Travis H Stracker*,1 The regulation of chromatin structure is critical for a wide range of essential cellular processes. The Tousled-like kinases, TLK1 and TLK2, regulate ASF1, a histone H3/H4 chaperone, and likely other substrates, and their activity has been implicated in transcription, DNA replication, DNA repair, RNA interference, cell cycle progression, viral latency, chromosome segregation and mitosis. However, little is known about the functions of TLK activity in vivo or the relative functions of the highly similar TLK1 and TLK2 in any cell type. To begin to address this, we have generated Tlk1- and Tlk2-deficient mice. We found that while TLK1 was dispensable for murine viability, TLK2 loss led to late embryonic lethality because of placental failure. TLK2 was required for normal trophoblast differentiation and the phosphorylation of ASF1 was reduced in placentas lacking TLK2. Conditional bypass of the placental phenotype allowed the generation of apparently healthy Tlk2-deficient mice, while only the depletion of both TLK1 and TLK2 led to extensive genomic instability, indicating that both activities contribute to genome maintenance. Our data identifies a specific role for TLK2 in placental function during mammalian development and suggests that TLK1 and TLK2 have largely redundant roles in genome maintenance.
  • High Throughput Computational Mouse Genetic Analysis

    High Throughput Computational Mouse Genetic Analysis

    bioRxiv preprint doi: https://doi.org/10.1101/2020.09.01.278465; this version posted January 22, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. High Throughput Computational Mouse Genetic Analysis Ahmed Arslan1+, Yuan Guan1+, Zhuoqing Fang1, Xinyu Chen1, Robin Donaldson2&, Wan Zhu, Madeline Ford1, Manhong Wu, Ming Zheng1, David L. Dill2* and Gary Peltz1* 1Department of Anesthesia, Stanford University School of Medicine, Stanford, CA; and 2Department of Computer Science, Stanford University, Stanford, CA +These authors contributed equally to this paper & Current Address: Ecree Durham, NC 27701 *Address correspondence to: [email protected] bioRxiv preprint doi: https://doi.org/10.1101/2020.09.01.278465; this version posted January 22, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Background: Genetic factors affecting multiple biomedical traits in mice have been identified when GWAS data that measured responses in panels of inbred mouse strains was analyzed using haplotype-based computational genetic mapping (HBCGM). Although this method was previously used to analyze one dataset at a time; but now, a vast amount of mouse phenotypic data is now publicly available, which could lead to many more genetic discoveries. Results: HBCGM and a whole genome SNP map covering 53 inbred strains was used to analyze 8462 publicly available datasets of biomedical responses (1.52M individual datapoints) measured in panels of inbred mouse strains. As proof of concept, causative genetic factors affecting susceptibility for eye, metabolic and infectious diseases were identified when structured automated methods were used to analyze the output.
  • Rabbit Anti-Human ELOVL5 Polyclonal Antibody (DPABH-25302) This Product Is for Research Use Only and Is Not Intended for Diagnostic Use

    Rabbit Anti-Human ELOVL5 Polyclonal Antibody (DPABH-25302) This Product Is for Research Use Only and Is Not Intended for Diagnostic Use

    Rabbit anti-Human ELOVL5 polyclonal antibody (DPABH-25302) This product is for research use only and is not intended for diagnostic use. PRODUCT INFORMATION Antigen Description Condensing enzyme that catalyzes the synthesis of monounsaturated and of polyunsaturated very long chain fatty acids Acts specifically toward polyunsaturated acyl-CoA with the higher activity toward C18:3(n-6) acyl-CoA. Specificity BLAST analysis of the peptide immunogen showed no homology with other human proteins. Immunogen Synthetic 15 amino acid peptide from a region of Human ELOVL5 Isotype IgG Source/Host Rabbit Species Reactivity Human Purification Immunogen affinity purified Conjugate Unconjugated Applications IHC-P Format Liquid Size 50 μg Buffer Constituent: 99% PBS Preservative 0.1% Sodium Azide Storage Shipped at 4°C. Upon delivery aliquot and store at -80℃. Avoid freeze / thaw cycles. GENE INFORMATION Gene Name ELOVL5 ELOVL fatty acid elongase 5 [ Homo sapiens ] Official Symbol ELOVL5 Synonyms ELOVL5; ELOVL fatty acid elongase 5; ELOVL family member 5, elongation of long chain fatty acids (FEN1/Elo2, SUR4/Elo3 like, yeast); elongation of very long chain fatty acids protein 5; 45-1 Ramsey Road, Shirley, NY 11967, USA Email: [email protected] Tel: 1-631-624-4882 Fax: 1-631-938-8221 1 © Creative Diagnostics All Rights Reserved dJ483K16.1; HELO1; ELOVL FA elongase 5; fatty acid elongase 1; 3-keto acyl-CoA synthase ELOVL5; homolog of yeast long chain polyunsaturated fatty acid elongatio; homolog of yeast long chain polyunsaturated fatty acid elongation enzyme 2; ELOVL family member 5, elongation of long chain fatty acids (FEN1/Elo2, SUR4/Elo3-like, yeast); RP3-483K16.1; Entrez Gene ID 60481 Protein Refseq NP_001229757 UniProt ID Q9NYP7 Chromosome Location 6p21.1-p12.1 Pathway Biosynthesis of unsaturated fatty acids; Fatty Acyl-CoA Biosynthesis; Fatty acid biosynthesis, elongation, endoplasmic reticulum; Fatty acid elongation.